Valuation: CSL Limited

Market Cap 62.88B 57.27B 52.77B 48B 90.06B 5,823B 94.65B 642B 255B 3,180B 236B 231B 9,981B P/E 2027 *
21.6x
P/E 2028 * 19.6x
Enterprise Value 72.1B 65.67B 60.51B 55.04B 103B 6,676B 109B 736B 293B 3,646B 271B 265B 11,444B EV / Sales 2027 *
4.57x
EV / Sales 2028 * 4.4x
Free-Float
99.97%
Yield 2027 *
2.29%
Yield 2028 * 2.43%
1 day-1.28%
1 week-2.77%
Current month-1.71%
1 month+0.62%
3 months+17.23%
6 months+97.19%
Current year+14.27%
1 week 194.56
Extreme 194.56
202.52
1 month 191.55
Extreme 191.55
205.48
Current year 90
Extreme 90
205.48
1 year 90
Extreme 90
205.48
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 Free

Director

523 0.0001%
8/26/26 Free 317 0.0001% -
8/26/26 Free

Director

1,586 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%-2.77%+10.31%-23.17% 62.77B
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+25.73%+67.00% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+24.18%+50.18% 288B
+0.81%-4.08%-2.95%+31.59% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average +0.17%-4.56%+23.54%+65.76% 413B
Weighted average by Cap. +0.28%-5.15%+25.78%+86.19%

Financials

2027 *2028 *
Net sales 15.76B 14.35B 13.23B 12.03B 22.57B 1,459B 23.72B 161B 63.98B 797B 59.13B 57.88B 2,502B 16.31B 14.85B 13.69B 12.45B 23.36B 1,510B 24.55B 167B 66.2B 825B 61.19B 59.9B 2,589B
Net income 2.82B 2.57B 2.37B 2.15B 4.04B 261B 4.25B 28.81B 11.45B 143B 10.58B 10.36B 448B 3.13B 2.85B 2.63B 2.39B 4.49B 290B 4.72B 32B 12.72B 158B 11.75B 11.51B 497B
Net Debt 9.22B 8.39B 7.73B 7.04B 13.2B 853B 13.87B 94.13B 37.41B 466B 34.58B 33.85B 1,463B 8.83B 8.04B 7.41B 6.74B 12.64B 817B 13.28B 90.15B 35.83B 446B 33.12B 32.42B 1,401B
Projected Income Statement - Annual - CSL Limited
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-11-20 A$197.29 -1.28% 1,525,418
26-11-19 A$199.85 +0.24% 1,079,874
26-11-18 A$199.38 -0.09% 767,508
26-11-17 A$199.55 -1.47% 882,185
26-11-16 A$202.52 -0.20% 655,770
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - CSL Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
131.07USD
Average target price
134.60USD
Spread / Average Target
+2.69%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CSL Limited